StonvexLoading…
StonvexStonvexStonvexCore line items from RXRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $74.68M | $58.84M | $44.58M | $39.84M |
Operating Income | $-648.13M | $-479.00M | $-350.06M | $-245.73M |
Net Income | $-644.76M | $-463.66M | $-328.07M | $-239.48M |
EPS (Diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
Total Assets | $1.47B | $1.45B | $653.70M | $701.29M |
Total Liabilities | $343.26M | $413.82M | $190.26M | $215.48M |
Cash & Equivalents | $743.29M | $594.35M | $391.56M | $549.91M |
Free Cash Flow OCF − CapEx | $-378.28M | $-372.87M | $-299.74M | $-120.58M |
Shares Outstanding | 528.18M | 396.80M | 234.27M | 191.02M |